Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.
Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS.
Nastoupil LJ, et al. Among authors: neelapu ss.
Blood Adv. 2022 Feb 22;6(4):1143-1151. doi: 10.1182/bloodadvances.2021006240.
Blood Adv. 2022.
PMID: 35015819
Free PMC article.
Clinical Trial.